Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study of Chidamide Plus DICE Regimen for Patients With Relapse or Refractory B-cell Non-Hodgkin's Lymphoma (NHL)

NCT03105596 is registered in ClinicalTrials.gov with Peking University as lead sponsor.

NCT NCT03105596
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03105596 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study of Chidamide Plus DICE Regimen for Patients With Relapse or Refractory B-cell Non-Hodgkin's Lymphoma (NHL)
Lead sponsor
Peking University
Phase
Phase 2
Overall status
Unknown status
Start date
April 11, 2017
Completion date
September 30, 2019
Enrollment
46 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell non-hodgkin's lymphoma